Chikungunya virus and prospects for a vaccine

Scott Weaver, Jorge E. Osorio, Jill A. Livengood, Rubing Chen, Dan T. Stinchcomb

Research output: Contribution to journalArticle

151 Scopus citations

Abstract

In 2004, chikungunya virus (CHIKV) re-emerged from East Africa to cause devastating epidemics of debilitating and often chronic arthralgia that have affected millions of people in the Indian Ocean Basin and Asia. More limited epidemics initiated by travelers subsequently occurred in Italy and France, as well as human cases exported to most regions of the world, including the Americas where CHIKV could become endemic. Because CHIKV circulates during epidemics in an urban mosquito-human cycle, control of transmission relies on mosquito abatement, which is rarely effective. Furthermore, there is no antiviral treatment for CHIKV infection and no licensed vaccine to prevent disease. Here, we discuss the challenges to the development of a safe, effective and affordable chikungunya vaccine and recent progress toward this goal.

Original languageEnglish (US)
Pages (from-to)1087-1101
Number of pages15
JournalExpert Review of Vaccines
Volume11
Issue number9
DOIs
StatePublished - Sep 2012

    Fingerprint

Keywords

  • alphavirus
  • antibody
  • chikungunya
  • emergence
  • evolution
  • mosquito
  • vaccine

ASJC Scopus subject areas

  • Immunology
  • Drug Discovery
  • Pharmacology
  • Molecular Medicine

Cite this

Weaver, S., Osorio, J. E., Livengood, J. A., Chen, R., & Stinchcomb, D. T. (2012). Chikungunya virus and prospects for a vaccine. Expert Review of Vaccines, 11(9), 1087-1101. https://doi.org/10.1586/erv.12.84